{"id":53934,"date":"2026-01-13T20:27:56","date_gmt":"2026-01-13T12:27:56","guid":{"rendered":"https:\/\/flcube.com\/?p=53934"},"modified":"2026-01-13T20:27:57","modified_gmt":"2026-01-13T12:27:57","slug":"chinas-nhsa-launches-pre-communication-pilot-for-reference-drugs-targeting-category-1-innovative-drugs","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=53934","title":{"rendered":"China\u2019s NHSA Launches Pre\u2011Communication Pilot for Reference Drugs, Targeting Category\u202f1 Innovative Drugs"},"content":{"rendered":"\n<p>China\u2019s <strong>National Healthcare Security Administration (NHSA)<\/strong> released the <strong>\u201cMeasures for Pre\u2011Communication on Reference Drugs (draft proposal)\u201d<\/strong> for public feedback until <strong>16\u202fJan\u202f2026<\/strong>, establishing a formal early\u2011consultation mechanism to stabilize market expectations and enhance the scientific rigor of <strong>National Reimbursement Drug List (NRDL)<\/strong> negotiations.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-regulatory-milestone\">Regulatory Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Agency<\/strong><\/td><td>NHSA (China)<\/td><\/tr><tr><td><strong>Document<\/strong><\/td><td>Measures for Pre\u2011Communication on Reference Drugs (draft)<\/td><\/tr><tr><td><strong>Status<\/strong><\/td><td>Open for public feedback<\/td><\/tr><tr><td><strong>Feedback Deadline<\/strong><\/td><td>16\u202fJan\u202f2026<\/td><\/tr><tr><td><strong>Implementation<\/strong><\/td><td>Pilot launch anticipated Q2\u202f2026<\/td><\/tr><tr><td><strong>Scope<\/strong><\/td><td>Category\u202f1 new drugs (chemical, therapeutic biologics, traditional Chinese medicines)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-policy-context-amp-market-problem\">Policy Context &amp; Market Problem<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Reference Drug Role:<\/strong> Benchmark for pharmacoeconomic and real\u2011world evidence studies; anchor for calculating NRDL reimbursement prices<\/li>\n\n\n\n<li><strong>Current Process:<\/strong> Companies propose reference drugs during NRDL adjustment; experts evaluate and may diverge from proposals<\/li>\n\n\n\n<li><strong>Industry Pain Point: ~15\u201120\u202f% of drugs<\/strong> face a mismatch between company\u2011proposed and expert\u2011selected references, rendering pre\u2011prepared pharmacoeconomic reports non\u2011comparable and forcing costly, time\u2011consuming revisions<\/li>\n\n\n\n<li><strong>International Precedent:<\/strong> Similar pre\u2011submission consultation mechanisms exist in <strong>Germany (AMNOG)<\/strong>, <strong>France (HAS)<\/strong>, and <strong>Japan (Chuikyo)<\/strong>, improving predictability for manufacturers<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-pilot-program-details\">Pilot Program Details<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Feature<\/th><th>Specification<\/th><\/tr><\/thead><tbody><tr><td><strong>Eligible Products<\/strong><\/td><td>Category\u202f1 new drugs with <strong>marketing authorization applications (MAAs) accepted<\/strong> and <strong>technical review passed<\/strong> by NMPA<\/td><\/tr><tr><td><strong>Timing<\/strong><\/td><td>Pre\u2011communication occurs <strong>6\u201112\u202fmonths before formal NRDL cycle<\/strong><\/td><\/tr><tr><td><strong>Deliverable<\/strong><\/td><td>NHSA\u2011facilitated expert panel issues <strong>non\u2011binding suggested reference drug<\/strong> and study guidance<\/td><\/tr><tr><td><strong>Benefits<\/strong><\/td><td>Allows sponsors to <strong>design pharmacoeconomic studies<\/strong> confidently, reducing risk of protocol amendments<\/td><\/tr><tr><td><strong>Workload Management<\/strong><\/td><td>Pilot limited to ~30\u201140 Category\u202f1 drugs annually; scalable based on performance<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-impact-amp-financial-implications\">Market Impact &amp; Financial Implications<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Metric<\/th><th>2025E<\/th><th>2026E<\/th><th>2027E<\/th><\/tr><\/thead><tbody><tr><td><strong>Category\u202f1 New Drug Approvals<\/strong><\/td><td>32<\/td><td>35<\/td><td>38<\/td><\/tr><tr><td><strong>NRDL Inclusion Rate<\/strong><\/td><td>45\u202f%<\/td><td>55\u202f%<\/td><td>60\u202f%<\/td><\/tr><tr><td><strong>Avg. Revenue Lift Post\u2011NRDL<\/strong><\/td><td>3.2\u00d7<\/td><td>3.5\u00d7<\/td><td>3.8\u00d7<\/td><\/tr><tr><td><strong>Time Saved by Pre\u2011Communication<\/strong><\/td><td>\u2013<\/td><td>6\u20118\u202fmonths<\/td><td>8\u201110\u202fmonths<\/td><\/tr><tr><td><strong>Value of Accelerated Access (per drug)<\/strong><\/td><td>\u2013<\/td><td>\u00a5280\u2011420\u202fM<\/td><td>\u00a5320\u2011480\u202fM<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Pharma Industry Benefit:<\/strong> Early reference drug clarity could <strong>reduce development costs<\/strong> for health economics studies by <strong>\u00a52\u20115\u202fmillion per product<\/strong> and shorten time\u2011to\u2011market by up to 10\u202fmonths<\/li>\n\n\n\n<li><strong>Innovation Incentive:<\/strong> Mechanism particularly supports <strong>first\u2011in\u2011class therapies<\/strong> where no clear comparator exists, stabilizing pricing expectations<\/li>\n\n\n\n<li><strong>Investor Confidence:<\/strong> Greater predictability in NRDL outcomes may <strong>lower regulatory risk premiums<\/strong> for China\u2011focused biotech valuations<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-competitive-landscape\">Competitive Landscape<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Company<\/th><th>Recent Category\u202f1 Launch<\/th><th>NRDL Outcome (2025)<\/th><\/tr><\/thead><tbody><tr><td><strong>Innovent Bio<\/strong><\/td><td>TYVYT (sintilimab)<\/td><td>Included, 63\u202f% price cut<\/td><\/tr><tr><td><strong>Junshi Bio<\/strong><\/td><td>Toripalimab<\/td><td>Included, 60\u202f% price cut<\/td><\/tr><tr><td><strong>BeiGene<\/strong><\/td><td>BGB\u2011167 (BTK inhibitor)<\/td><td>Negotiations pending<\/td><\/tr><tr><td><strong>CStone Pharma<\/strong><\/td><td>Sugemalimab<\/td><td>Included, 54\u202f% price cut<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Differentiation:<\/strong> Pre\u2011communication gives <strong>smaller biotechs<\/strong> (e.g., CAR\u2011T, gene therapy developers) a clearer path to justify premium pricing vs. established competitors<\/li>\n\n\n\n<li><strong>Policy Alignment:<\/strong> Pilot reinforces China\u2019s \u201c<strong>innovation\u2011friendly<\/strong>\u201d stance, balancing cost containment with support for domestic R&amp;D<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding NHSA policy implementation timelines, drug approval rates, and revenue impacts. Actual outcomes may differ due to public feedback revisions, bureaucratic delays, and evolving NRDL negotiation dynamics.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>China\u2019s National Healthcare Security Administration (NHSA) released the \u201cMeasures for Pre\u2011Communication on Reference Drugs (draft&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[4],"tags":[],"class_list":["post-53934","post","type-post","status-publish","format-standard","hentry","category-policy-regulatory"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>China\u2019s NHSA Launches Pre\u2011Communication Pilot for Reference Drugs, Targeting Category\u202f1 Innovative Drugs - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"China\u2019s National Healthcare Security Administration (NHSA) released the \u201cMeasures for Pre\u2011Communication on Reference Drugs (draft proposal)\u201d for public feedback until 16\u202fJan\u202f2026, establishing a formal early\u2011consultation mechanism to stabilize market expectations and enhance the scientific rigor of National Reimbursement Drug List (NRDL) negotiations.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=53934\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"China\u2019s NHSA Launches Pre\u2011Communication Pilot for Reference Drugs, Targeting Category\u202f1 Innovative Drugs\" \/>\n<meta property=\"og:description\" content=\"China\u2019s National Healthcare Security Administration (NHSA) released the \u201cMeasures for Pre\u2011Communication on Reference Drugs (draft proposal)\u201d for public feedback until 16\u202fJan\u202f2026, establishing a formal early\u2011consultation mechanism to stabilize market expectations and enhance the scientific rigor of National Reimbursement Drug List (NRDL) negotiations.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=53934\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-01-13T12:27:56+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-01-13T12:27:57+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53934#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53934\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"China\u2019s NHSA Launches Pre\u2011Communication Pilot for Reference Drugs, Targeting Category\u202f1 Innovative Drugs\",\"datePublished\":\"2026-01-13T12:27:56+00:00\",\"dateModified\":\"2026-01-13T12:27:57+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53934\"},\"wordCount\":467,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"articleSection\":[\"Policy \\\/ Regulatory\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=53934#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53934\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=53934\",\"name\":\"China\u2019s NHSA Launches Pre\u2011Communication Pilot for Reference Drugs, Targeting Category\u202f1 Innovative Drugs - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-01-13T12:27:56+00:00\",\"dateModified\":\"2026-01-13T12:27:57+00:00\",\"description\":\"China\u2019s National Healthcare Security Administration (NHSA) released the \u201cMeasures for Pre\u2011Communication on Reference Drugs (draft proposal)\u201d for public feedback until 16\u202fJan\u202f2026, establishing a formal early\u2011consultation mechanism to stabilize market expectations and enhance the scientific rigor of National Reimbursement Drug List (NRDL) negotiations.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53934#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=53934\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53934#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"China\u2019s NHSA Launches Pre\u2011Communication Pilot for Reference Drugs, Targeting Category\u202f1 Innovative Drugs\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"China\u2019s NHSA Launches Pre\u2011Communication Pilot for Reference Drugs, Targeting Category\u202f1 Innovative Drugs - Insight, China&#039;s Pharmaceutical Industry","description":"China\u2019s National Healthcare Security Administration (NHSA) released the \u201cMeasures for Pre\u2011Communication on Reference Drugs (draft proposal)\u201d for public feedback until 16\u202fJan\u202f2026, establishing a formal early\u2011consultation mechanism to stabilize market expectations and enhance the scientific rigor of National Reimbursement Drug List (NRDL) negotiations.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=53934","og_locale":"en_US","og_type":"article","og_title":"China\u2019s NHSA Launches Pre\u2011Communication Pilot for Reference Drugs, Targeting Category\u202f1 Innovative Drugs","og_description":"China\u2019s National Healthcare Security Administration (NHSA) released the \u201cMeasures for Pre\u2011Communication on Reference Drugs (draft proposal)\u201d for public feedback until 16\u202fJan\u202f2026, establishing a formal early\u2011consultation mechanism to stabilize market expectations and enhance the scientific rigor of National Reimbursement Drug List (NRDL) negotiations.","og_url":"https:\/\/flcube.com\/?p=53934","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-01-13T12:27:56+00:00","article_modified_time":"2026-01-13T12:27:57+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=53934#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=53934"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"China\u2019s NHSA Launches Pre\u2011Communication Pilot for Reference Drugs, Targeting Category\u202f1 Innovative Drugs","datePublished":"2026-01-13T12:27:56+00:00","dateModified":"2026-01-13T12:27:57+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=53934"},"wordCount":467,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"articleSection":["Policy \/ Regulatory"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=53934#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=53934","url":"https:\/\/flcube.com\/?p=53934","name":"China\u2019s NHSA Launches Pre\u2011Communication Pilot for Reference Drugs, Targeting Category\u202f1 Innovative Drugs - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-01-13T12:27:56+00:00","dateModified":"2026-01-13T12:27:57+00:00","description":"China\u2019s National Healthcare Security Administration (NHSA) released the \u201cMeasures for Pre\u2011Communication on Reference Drugs (draft proposal)\u201d for public feedback until 16\u202fJan\u202f2026, establishing a formal early\u2011consultation mechanism to stabilize market expectations and enhance the scientific rigor of National Reimbursement Drug List (NRDL) negotiations.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=53934#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=53934"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=53934#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"China\u2019s NHSA Launches Pre\u2011Communication Pilot for Reference Drugs, Targeting Category\u202f1 Innovative Drugs"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/53934","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=53934"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/53934\/revisions"}],"predecessor-version":[{"id":53935,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/53934\/revisions\/53935"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=53934"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=53934"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=53934"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}